Stock Track | FANGZHOU JIANKE Soars 5.71% Intraday on Strong 2025 Results and AI Strategy

Stock Track

Mar 20

FANGZHOU JIANKE's stock price soared 5.71% during intraday trading on Friday, following the release of the company's 2025 annual results which showed a significant turnaround to profitability and robust revenue growth.

The company reported revenue of RMB3.53 billion for 2025, representing a 30.2% year-on-year increase, and achieved a net profit of approximately RMB12 million, marking a recovery from a net loss in the previous year. This performance exceeded market expectations and was driven by growth across its online retail pharmacy, wholesale, and comprehensive medical services segments.

Fangzhou's AI-driven chronic disease management strategy appears to be gaining traction, with the company reporting a 35% increase in average monthly active users to 13.7 million. The launch of its "XingShi" large language model and strategic partnerships with pharmaceutical companies like Novo Nordisk and Innovent Biologics have strengthened its position in the growing AI-enabled healthcare market in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1121625055"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121625055\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121625055?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121625055","market":"sg","top_or_hot":-1,"title":"Stock Track | FANGZHOU JIANKE Soars 5.71% Intraday on Strong 2025 Results and AI Strategy","media":"Stock Track","content":"<p>FANGZHOU JIANKE's stock price soared 5.71% during intraday trading on Friday, following the release of the company's 2025 annual results which showed a significant turnaround to profitability and robust revenue growth.</p><p>The company reported revenue of RMB3.53 billion for 2025, representing a 30.2% year-on-year increase, and achieved a net profit of approximately RMB12 million, marking a recovery from a net loss in the previous year. This performance exceeded market expectations and was driven by growth across its online retail pharmacy, wholesale, and comprehensive medical services segments.</p><p>Fangzhou's AI-driven chronic disease management strategy appears to be gaining traction, with the company reporting a 35% increase in average monthly active users to 13.7 million. The launch of its \"XingShi\" large language model and strategic partnerships with pharmaceutical companies like Novo Nordisk and Innovent Biologics have strengthened its position in the growing AI-enabled healthcare market in China.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | FANGZHOU JIANKE Soars 5.71% Intraday on Strong 2025 Results and AI Strategy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | FANGZHOU JIANKE Soars 5.71% Intraday on Strong 2025 Results and AI Strategy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-20 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FANGZHOU JIANKE's stock price soared 5.71% during intraday trading on Friday, following the release of the company's 2025 annual results which showed a significant turnaround to profitability and robust revenue growth.</p><p>The company reported revenue of RMB3.53 billion for 2025, representing a 30.2% year-on-year increase, and achieved a net profit of approximately RMB12 million, marking a recovery from a net loss in the previous year. This performance exceeded market expectations and was driven by growth across its online retail pharmacy, wholesale, and comprehensive medical services segments.</p><p>Fangzhou's AI-driven chronic disease management strategy appears to be gaining traction, with the company reporting a 35% increase in average monthly active users to 13.7 million. The launch of its \"XingShi\" large language model and strategic partnerships with pharmaceutical companies like Novo Nordisk and Innovent Biologics have strengthened its position in the growing AI-enabled healthcare market in China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06086","symbol_name":"方舟健客","start_time":0,"source_url":"","article_id":"1121625055","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121625055","pubTimestamp":1773971099,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"FANGZHOU JIANKE's stock price soared 5.71% during intraday trading on Friday, following the release of the company's 2025 annual results which showed a significant turnaround to profitability and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06086":"方舟健客"},"translate_title":"个股赛道|方舟建科盘中大涨5.71%2025业绩强劲及AI战略","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06086":1},"content_text":"FANGZHOU JIANKE's stock price soared 5.71% during intraday trading on Friday, following the release of the company's 2025 annual results which showed a significant turnaround to profitability and robust revenue growth.The company reported revenue of RMB3.53 billion for 2025, representing a 30.2% year-on-year increase, and achieved a net profit of approximately RMB12 million, marking a recovery from a net loss in the previous year. This performance exceeded market expectations and was driven by growth across its online retail pharmacy, wholesale, and comprehensive medical services segments.Fangzhou's AI-driven chronic disease management strategy appears to be gaining traction, with the company reporting a 35% increase in average monthly active users to 13.7 million. The launch of its \"XingShi\" large language model and strategic partnerships with pharmaceutical companies like Novo Nordisk and Innovent Biologics have strengthened its position in the growing AI-enabled healthcare market in China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}